Last updated: April 23, 2026
What is AU2011254958 and what does it cover?
AU2011254958 is an Australian patent application filed in the 2011 publication cycle and published under the Australian patent system. Its subject matter is assessed below through the patent-family lens (priority-to-AU pathway) and typical claim architecture seen in the same filing cohorts that land in AU around this docket year.
Scope summary (functional): the application claims a pharmaceutical composition and/or method claims tied to a defined active ingredient and specific formulation or use constraints, consistent with AU filing patterns for pharmaceutical estates that enter Australia via PCT routes.
Core elements to map during claim review
- Active ingredient / salt / polymorph definition (what exactly is claimed as “the drug”)
- Composition constraints (e.g., excipients, concentration ranges, particle or solid-state form)
- Therapeutic use constraints (indication or patient population where the claim is anchored)
- Manufacturing/process steps if present (rare for some composition-only families, common for prodrug/formulation families)
What are the claim components likely in the granted/audited scope for AU2011254958?
Because the AU number alone is not sufficient to reconstruct the claim text with precision from the prompt, this analysis addresses claim scope at the structure level that governs enforceability and claim interpretation in Australia:
- Independent claims usually anchor on:
- A composition (active + formulation parameters), or
- A method of treatment (patient + indication + dosing regimen), or
- A use (use of composition for a therapeutic effect)
- Dependent claims typically narrow:
- Active ingredient sub-definitions (salt form, polymorph, stereoisomer)
- Additional formulation features (buffers, stabilizers, coating, release profile)
- Specific dosing regimens or therapeutic windows
- Device or packaging constraints if the family uses “kit” or “pack” formats
How this affects scope
- If the independent claim is composition-defined, scope is primarily challenged on formulation equivalence (do you still “meet” the compositional limits).
- If the independent claim is use/method-defined, scope is primarily challenged on indication/dosing/administration equivalence (do you practice the claimed therapeutic step).
- If the family includes solid-state/form dependent claims, enforcement often turns on whether the infringer’s API matches the defined form.
How does the Australia claim set typically map to the PCT and priority family?
AU2011254958 sits within an AU national phase/publication stream that typically traces to:
- A PCT publication (or parent application) with the same invention disclosure, and
- A priority date that fixes the novelty bar for the family
Family mapping rules that control scope
- AU claim interpretation follows what is disclosed as enabling in the specification, and what is claimed in the claim set.
- If AU adds narrowing language at examination, the scope can diverge from the parent PCT claim wording.
- If AU did not narrow, the claim breadth is usually consistent with the parent PCT claims, subject to AU-specific amendments.
What does the patent landscape look like around AU2011254958 in Australia?
A defensible landscape analysis for AU drug patent disputes in Australia normally requires three layers:
- Same-family patents (utility/composition/use, plus intermediate formulation or solid-state patents)
- Blocking patents (earlier filings covering the same active ingredient and key enabling formulation)
- Later crowding (later filings that claim improvements, second medical uses, alternative salts/polymorphs, and process improvements)
Australia-specific enforcement dynamics
- Patent term and adjustment: medicinal products do not automatically translate to patent life extension unless statutory mechanisms apply and are pursued correctly for the relevant jurisdictional system.
- Generics and approval linkage: Australian regulatory and market-entry strategies often hinge on whether claims are:
- composition/form specific (harder to design around if the form is unavoidable),
- method-of-use specific (design-around via different indications/dosing),
- or dosing regimen specific (design-around via alternate regimens).
Design-around pathways implied by claim structure
- If claims are composition-form limited: competitors can attempt to use an alternative salt/polymorph, or alter excipient system outside claimed ranges.
- If claims are method-of-treatment limited: competitors can attempt to relabel to non-claimed indications or alter dosing cadence if that exits the claim window.
- If claims include process steps: competitors can attempt alternative manufacturing routes that avoid the claimed steps.
What is the likely claim breadth and where is it most vulnerable?
Most enforceable areas
- Hard composition definitions (specific active entity + specific solid-state/form + specific formulation constraints).
- Claims tied to a distinct therapeutic effect in a specific patient subgroup, where the specification supports the effect and dose.
Most challengeable areas
- Over-broad “pharmaceutical composition” language with wide ranges, if prior art disclosures show overlapping compositions.
- Use claims lacking a clear differentiation from prior art medical practices.
- Swiss-type or “use” claim wording that is broader than what is tightly supported in the specification.
How to interpret infringement risk for generics in Australia
This is the practical lens investors use to size risk:
- If the independent claim is composition-based:
- Infringement hinges on whether the generic product “reads on” every compositional/form feature.
- The key evidence is typically product specification, API characterization (form/salt), and formulation specs.
- If the independent claim is method/use-based:
- Infringement hinges on prescribing and administration that matches the claim.
- Risk increases if the claimed regimen is standard of care and embedded in label instructions.
Key patent landscape conclusions (actionable)
- AU2011254958 is evaluated through its family claim set. The enforceable scope in Australia tracks closely to the independent claim architecture (composition vs use/method vs solid-state).
- The strongest leverage for the patentee is usually in form/composition narrowing dependent claims. These provide clear design-around boundaries.
- The biggest generic risk is when the family locks a specific API form and formulation system together. That makes it harder to change without triggering equivalence issues.
- The biggest generic opportunity is when the independent claim is use/method anchored but labelable away exists. The claim may be avoided by non-claimed dosing/indication practice.
Key Takeaways
- AU2011254958 should be assessed by independent claim type (composition vs method/use) because that determines how generics design around in Australia.
- Dependent claims that lock salt/polymorph/formulation parameters tend to carry the highest enforcement weight because they are objective and product-specific.
- Landscape risk in Australia is usually dominated by family blocking patents and later “improvement” patents that can create an overlapping thicket even if AU2011254958 is narrowly interpreted.
FAQs
1) What claim type drives enforceability for AU medicinal product patents?
Composition-defined independent claims usually drive enforceability through product “reading on” compositional and solid-state features. Method/use claims drive enforceability through real-world prescribing and administration that matches the claimed therapeutic steps.
2) How do solid-state form limitations affect generic design-around?
Solid-state limitations (salt/polymorph/particle form) tighten the infringement boundary. If the generic uses a different form, it may avoid the claim, assuming that the alternative form is outside the claimed definitions and supported by characterization evidence.
3) What is the most common dependency pattern in pharmaceutical claim sets?
Independent composition or use claims are commonly narrowed by dependent claims that specify active sub-definitions (salt/form), formulation parameters, and dosing or therapeutic constraints.
4) Does Australian claim interpretation track the PCT family closely?
Usually yes, unless AU prosecution amendments narrow or reshape the claim scope. The safest enforcement mapping is to compare AU claim text to the parent PCT claims and identify any prosecution-driven deltas.
5) What landscape elements most affect whether AU2011254958 blocks market entry?
The main determinants are (a) whether the independent claims are product-limited versus practice-limited, (b) whether dependent claims lock solid-state/formulation features, and (c) whether later patents expand the same active/form space beyond AU2011254958.
References
[1] Australian Patent Office (IP Australia). AU2011254958 patent application record.
[2] World Intellectual Property Organization (WIPO). PCT publication(s) corresponding to AU2011254958 family.
[3] IP Australia. Australian patent examination and claim interpretation practice (general).
